Pharmacosmos A/S is delighted to announce that marketing approval has been granted for Monoferric^TM?(global brand name Monofer?) in Canada. Monoferric^TM?is approved for the treatment of iron deficiency anemia in adult patients who have intolerance or unresponsiveness to oral iron therapy. Monoferric will be available in Canada in November, 2018. In 2015 Pharmacosmos entered into an agreement with Pfizer Canada who have the exclusive commercialisation rights to Monoferric^TM?in Canada. The structure of Monoferric^TM?is designed to be different from other intravenous iron replacement therapies, with a matrix structure of linear isomaltoside chains interspersed with Fe³⁺, allowing the possibility to administer high doses of iron, often in only one visit to the doctor, for the benefit and convenience of patients, healthcare professionals and hospital budgets. Michael Ryde, VP?Partners & Marketing?at Pharmacosmos?commented:??We are excited by the opportunity to introduce Monoferric^TM?in Canada (known as MONOFER^??in other countries) with Pfizer as our partner. We believe that Monoferric^TM?will serve unmet clinical needs with a clear potential to improve outcomes and convenience for Canadian patients and we have great confidence in Pfizer to establish Monoferric^TM?as a leading IV iron brand in Canada.? Cole Pinnow, General Manager, Pfizer Global Established Pharma Business in Canada, said: ?We are pleased to be able to launch Monoferric^TM?in Canada later this year and believe strongly that this new treatment option reinforces Pfizer?s ongoing commitment to bringing innovative solutions to the lives of Canadian patients.? ?For more information, please contact: Michael Ryde Vice President, Partners & Marketing M: +45 26 48 74 16 T:? +45 59 48 59 59 mry@pharmacosmos.com For media/external inquiries Fonnesbech & Estrup Adam Estrup Tel: +45 28 74 87 10 adam@estrup.dk